Ovulation induction for those with the polycystic ovarian syndrome has advanced significantly (PCOS). Since the cumulative pregnancy rate in carefully chosen patients approaches that of healthy women, clomiphene citrate continues to be the first line of treatment for all an ovulatory women with PCOS. The development of low-dose regimens has heralded a new era in the treatment of anovulation linked to PCOS. Human urine gonadotrophins have been utilized widely for ovulation induction. The primary benefits and drawbacks of the various approaches and regimens now employed for ovulation induction in PCOS patients, including clomiphene citrate, gonadotrophins, pulsatile Gonadotrophin-Releasing Hormone (GnRH), and GnRH agonists, are covered in this article. Further research is required on novel medications to treat type 2 diabetes because many metabolic therapies had initial promise but later disappointed (troglitozone or d-chiro-inositol). Obstetric outcomes have been inconsistently affected by weight loss strategies, whether they are lifestylerelated, include obesity medications, or involve bariatric surgery. Combination medicines (such metformin and clomiphene combined) may help some patient subgroups more when used for metabolic and reproductive treatments.
